ESC ranking puts AstraZeneca's Brilinta ahead of Lilly's Effient and clopidogrel
This article was originally published in Scrip
The European Society of Cardiology has backed the use of AstraZeneca's new oral antiplatelet agent ticagrelor (Brilinta/Brilique), giving it its highest class 1 recommendation in its latest guidelines for the treatment of ST-elevation acute myocardial infarction (STEMI).
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.